A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation

Wallström, Mats; Nilsson, Fredrik; Hirsch, Jan–M.

doi:10.1080/09652140050111096

Cited by 29 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reasons given by unsuccessful patients for not persisting with NRT (3 complained they were tired of chewing gum, and 5 claimed the gum was not effective) suggest that further improvements may be made by, for example, offering other nicotine replacement products such as an inhaler [16, 17]or a sublingual tablet [18]instead of chewing gum. And a combination of fixed-dose (nicotine patch) plus self-administered NRT (inhaler, gum, nasal spray or sublingual tablet) may benefit some smokers who have already tried single NRT [19].…”

Section: Discussionmentioning

confidence: 99%

Harm Reduction – A Treatment Approach for Resistant Smokers with Tobacco-Related Symptoms

et al. 2002

View full text Add to dashboard Cite

Smokers with chronic obstructive pulmonary disease (COPD) appear to represent a hard-core group, and this presents a dilemma for chest physicians. A reduction in cigarette smoking benefits health, and nicotine replacement therapy (NRT) can aid smoking reduction. Hence we studied the efficacy of nicotine gum in helping hard-core smokers with severe COPD to quit. Seventeen smokers with severe COPD (FEV₁ 38–47% of predicted normal) who smoked >30 cigarettes/day but were unable to quit were encouraged to reduce their smoking as much as possible by using 4-mg nicotine gum. Five gradually reduced their daily tobacco consumption and, 18 months after starting NRT, were smoking an average of 6 cigarettes/day while still using nicotine gum. Compared to baseline, their respiratory symptoms had improved, and both FEV₁ and FVC had increased. There was no improvement in pulmonary function in the group of smokers who did not reduce their cigarette consumption. No adverse events relating to nicotine occurred among the patients who used NRT to reduce their smoking. We propose that this reduction approach should be considered for patients with respiratory disease who are unable or unwilling to stop smoking.

show abstract

Section: Discussionmentioning

confidence: 99%

Harm Reduction – A Treatment Approach for Resistant Smokers with Tobacco-Related Symptoms

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The pharmacokinetics of the 2-mg sublingual tablet are very similar to those of the 2-mg gum (i.e. similar nicotine concentrations are achieved with both formulations) [35]. In one clinical trial, highly dependent smokers (FTQ 5 7) were randomized to receive two tablets/hour, and the low dependent smokers (FTQ 5 7) were randomized to receive one tablet/hour.…”

Section: Nicotine Sublingual Tabletmentioning

confidence: 98%

“…Complete abstinence rates were 50% vs. 29% at 6 weeks (p 5 0.001), 42% vs. 23% at 3 months (p 5 0.001) and 33% vs. 18% at 6 months (p 5 0.005). When analyzed with respect to level of baseline nicotine dependence, the tablet was more efficacious for highly dependent smokers [35]. The major side effects of the nicotine tablet included mouth irritation, hiccups and dyspepsia.…”

Section: Nicotine Sublingual Tabletmentioning

confidence: 99%

Pharmacotherapies to enhance smoking cessation during pregnancy

Oncken¹,

Kranzler

2003

Drug and Alcohol Review

View full text Add to dashboard Cite

Smoking during pregnancy is a significant public health concern. Maternal smoking increases the risk of spontaneous abortion, low birth weight, premature delivery, sudden infant death syndrome and learning and behavioral problems in the offspring. Unfortunately, the majority of pregnant women do not quit smoking during pregnancy. Although pharmacotherapy may improve smoking cessation rates in pregnancy, very few studies exist that have studied the safety and efficacy of medications to treat pregnant smokers. This article reviews the available safety and efficacy data for the use in pregnancy of the five first-line therapies and two second-line therapies that are recommended for smoking cessation in non-pregnant smokers. Other promising nicotine replacement therapies are also reviewed. Ultimately, the choice whether to use pharmacotherapy for smoking cessation should be made jointly by the pregnant smoker and her health care provider. This article reviews factors that may be considered when prescribing pharmacotherapy to pregnant smokers (i.e. the role of behavioral counseling, identification of appropriate patients, potential advantages and disadvantages of each of the pharmacotherapies, proposed monitoring strategies, dose and duration and goals of treatment). More research regarding the safety and efficacy of pharmacotherapy during pregnancy is needed to define the risk/benefit profile of each medication for use in smoking cessation in pregnant women.

show abstract

“…In both low-and high-dependency smokers, treatment with the lozenge showed lower craving within the first 2 weeks of craving when it is at the peak [93,94]. These results starkly contrast with that for the sublingual tablet which only reduced craving and withdrawal in high or moderately dependent smokers [95,96]. In the highly dependent smokers, the 4-mg lozenge was particularly robust in suppressing withdrawal symptoms and craving even in the second week of abstinence, producing high quit rates, reducing weight gain, and showed a significant difference between placebo groups and active-treated groups [93,94].…”

Section: Clinical Studiesmentioning

confidence: 72%

Tablets and Other Solid Dosage Forms for Systemic Oral Mucosal Drug Delivery

Rane¹,

Moe²

2015

Advances in Delivery Science and Technology

View full text Add to dashboard Cite

A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation

Abstract: The nicotine sublingual tablet increased the smoking cessation rate compared to placebo, reduced craving in highly dependent smokers and was well tolerated.

Cited by 29 publications

References 0 publications

Harm Reduction – A Treatment Approach for Resistant Smokers with Tobacco-Related Symptoms

Harm Reduction – A Treatment Approach for Resistant Smokers with Tobacco-Related Symptoms

Pharmacotherapies to enhance smoking cessation during pregnancy

Tablets and Other Solid Dosage Forms for Systemic Oral Mucosal Drug Delivery

Contact Info

Product

Resources

About